References

Asthma and Lung UK. Press release: Lung conditions kill more people in the UK than anywhere in Western Europe. 2022. https://www.asthmaandlung.org.uk/media/press-releases/lung-conditions-kill-more-people-uk-anywhere-western-europe (accessed 20/01/2025)

Asthma and Lung UK. Your child's asthma review. 2024. https://www.asthmaandlung.org.uk/conditions/asthma/child/manage/review (accessed 22/01/2025)

Asthma and Lung UK. Asthma and your child. https://www.asthmaandlung.org.uk/conditions/asthma/child (accessed 22/01/2025)

BTS, NICE, SIGN. Algorithm E; pharmacological management of asthma in children under 5. 2024. https://www.nice.org.uk/guidance/ng245/resources/algorithm-e-pharmacological-management-of-asthma-in-children-under-5-bts-nice-sign-pdf-13556516369 (accessed 20/01/2025)

BTS, NICE, SIGN. Asthma: diagnosis, monitoring and chronic asthma management. NICE guideline [NG245]. 2024. https://www.nice.org.uk/guidance/NG245 (accessed 20/01/2025)

GINA. Global Strategy for Asthma Management and Prevention – 2024 update. 2024. https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf (accessed 21/01/2025)

Primary Care Respiratory Update. Primary Care Respiratory Society. 2024. https://www.pcrs-uk.org/pcru/autumnwinter-2024 (accessed 20/01/2025)

MHRA. Montelukast: reminder of the risk of neuropsychiatric reactions. 2024. https://www.gov.uk/drug-safety-update/montelukast-reminder-of-the-risk-of-neuropsychiatric-reactions (accessed 22/01/2025)

NICE. Babies, children and young people's experience of healthcare. NICE guideline [NG204]. 2021. https://www.nice.org.uk/guidance/ng204 (accessed 22/01/2025)

Qoltech. Asthma control questionnaire. https://www.qoltech.co.uk/acq.html (accessed 22/01/2025)

PCRS. On Demand webinar: The new BTS/SIGN/NICE guideline for asthma: What it means for you. 2025. https://www.pcrs-uk.org/resource/current/demand-webinar-new-btssignnice-guideline-asthma-what-it-means-you (accessed 22/01/2025)

Royal College of Paediatrics and Child Health. State of Child Health: Asthma. 2020. https://stateofchildhealth.rcpch.ac.uk/evidence/long-term-conditions/asthma/ (accessed 20/01/2025)

SIGN. Alternative diagnoses in wheezy children. [SIGN 244]. 2019. https://rightdecisions.scot.nhs.uk/asthma-pathway-bts-nice-sign-sign-244/diagnosis/alternative-diagnoses-in-wheezy-children/ (accessed 20/01/2025)

Clinical guidelines for the care of children aged under 5 with asthma: An overview of the recent national guidelines

02 February 2025
Volume 36 · Issue 2

Abstract

Heather Henry explains why it is critical that nurses in primary and community health services understand what has been described as a ‘sea change’ in the national guidelines for managing asthma

This is the first of 3 articles providing an in-depth overview of the recently updated British Thoracic Society (BTS), Scottish Intercollegiate Guidelines Network (SIGN), and National Institute for Health and Care Excellence (NICE) guidelines for the care of people with asthma, published on 27 November 2024. This article aims to equip nurses with the knowledge and tools needed to deliver evidence-based care and improve outcomes for children with asthma aged under 5 years.

Asthma is the most common long-term condition amongst children and young people and is one of the top ten reasons for emergency hospital admission in the UK (Royal College of Paediatrics and Child Health, 2020). Asthma and Lung UK reported (2022) that the UK has the worst death rate for lung conditions such as asthma and chronic obstructive pulmonary disease (COPD) than anywhere else in western Europe. Given how common is, and how poorly the UK compares, it is critical that nurses in primary and community services understand what has been described as a ‘sea change’ in national guidelines (Hickman, 2024; BTS/SIGN/NICE, 2024).

These new guidelines resolve longstanding differences between the previous BTS and SIGN guidelines, and NICE guidelines. In addition, health professionals describe the new guidelines as an opportunity for an ‘upgrade’ people's inhalers (PCRS, 2025). For example, for older children and adults, this might mean a move (where clinically indicated) towards maintenance and reliever therapy (MART) regimes, enabling people to receive controller medication alongside a long acting reliever with every dose, thus reducing the reliance on short acting bronchodilators (SABA), which can be associated with poor control and increased exacerbations (GINA, 2024). Diagnostic testing has also changed in those aged 5 and over, with a move towards blood eosinophils or fractional exhaled nitric oxide (FeNO) as the first line. The following paragraph and algorithm references refer to the 2024 BTS/SIGN/NICE guidelines.

Register now to continue reading

Thank you for visiting Practice Nursing and reading some of our peer-reviewed resources for general practice nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month